E-LIB Suche - Ergebnisse für: Thaçi, D.

1

Optical coherence tomography‐based imaging biomarkers for d..:

Ha‐Wissel, L. ; Graßhoff, H. ; Göb, M....
Journal of the European Academy of Dermatology and Venereology. , 2024

Link: https://doi.org/10.1111/..

2

Maintien de l'efficacité du bimékizumab pendant 52 semaines..:

Gossec, L. ; Tillett, W. ; Merola, J.F....
Revue du Rhumatisme. 90 (2023) - p. A185-A186 , 2023

Link: https://doi.org/10.1016/..

3

Efficacy of spesolimab for the treatment of generalized pus..:

Burden, A. D. ; Okubo, Y. ; Zheng, M....
Experimental Dermatology. 32 (2023) 8 - p. 1279-1283 , 2023

Link: https://doi.org/10.1111/..

4

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stra..:

Thyssen, J. P. ; Thaçi, D. ; Bieber, T....
Journal of the European Academy of Dermatology and Venereology. 37 (2023) 9 - p. 1871-1880 , 2023

Link: https://doi.org/10.1111/..

5

Estimands for atopic dermatitis clinical trials: Expert opi..:

Bissonnette, R. ; Eichenfield, L. F. ; Simpson, E....
Journal of the European Academy of Dermatology and Venereology. 37 (2023) 5 - p. 976-983 , 2023

Link: https://doi.org/10.1111/..

6

POSC7 Work Productivity and Activity Impairment for Patient..:

Thaçi, D ; Bagel, J ; Węgłowska, J...
Value in Health. 25 (2022) 1 - p. S33 , 2022

Link: https://doi.org/10.1016/..

7

Direct comparison of risankizumab and fumaric acid esters i..:

Thaçi, D. ; Eyerich, K. ; Pinter, A....
British Journal of Dermatology. 186 (2022) 1 - p. 30-39 , 2022

Link: https://doi.org/10.1111/..

8

Bimekizumab infection rates in patients with moderate to se..:

Armstrong, A ; Langley, RG ; Gordon, KB...
SKIN The Journal of Cutaneous Medicine. 6 (2022) 6 - p. s72 , 2022

Link: https://doi.org/10.25251..

9

Le bimékizumab améliore la qualité de vie chez les patients..:

Gossec, L. ; Gladman, D.D. ; Kristensen, L.E....
Revue du Rhumatisme. 89 (2022) - p. A39-A40 , 2022

Link: https://doi.org/10.1016/..

10

Maintenance of bimekizumab efficacy through 2 years in pati..:

Thaçi, D ; Armstrong, A ; Lebwohl, M...
SKIN The Journal of Cutaneous Medicine. 6 (2022) 6 - p. s71 , 2022

Link: https://doi.org/10.25251..

11

Five‐year efficacy and safety of tildrakizumab in patients ..:

Thaci, D. ; Piaserico, S. ; Warren, R.B....
British Journal of Dermatology. 185 (2021) 2 - p. 323-334 , 2021

Link: https://doi.org/10.1111/..

12

Association of sex and systemic therapy treatment outcomes ..:

Maul, J.‐T. ; Augustin, M. ; Sorbe, C....
British Journal of Dermatology. 185 (2021) 6 - p. 1160-1168 , 2021

Link: https://doi.org/10.1111/..

13

Low incidence rate of respiratory and viral infections over..:

Thaçi, D. ; Jullien, D. ; Egeberg, A....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 11 - p. , 2021

Link: https://doi.org/10.1111/..

14

Long-Term Improvements in Health-Related Quality of Life of..:

Thaçi, D ; Blauvelt, A ; Reich, K...
SKIN The Journal of Cutaneous Medicine. 5 (2021) 1 - p. s20 , 2021

Link: https://doi.org/10.25251..

15

Addressing challenges associated with long‐term topical tre..:

Lebwohl, M. ; Thaçi, D. ; Warren, R.B.
Journal of the European Academy of Dermatology and Venereology. 35 (2021) S1 - p. 35-41 , 2021

Link: https://doi.org/10.1111/..